Chronic Myeloid Leukemia (CML) Clinical Trial
Official title:
Chronic Myeloid Leukemia (CML) Real-Life Database
Establish the largest possible real-life cohort collecting long-term follow-up of a maximum number of CML patients in order to carry out observational studies: epidemiological, identification of subgroups according to their response to treatment, evaluation of new molecules in real life, therapeutic discontinuations, impact of the evolution of recommendations, etc.
Observational study collecting real-life clinico-biological data from patients with CML. Data are collected prospectively and retrospectively, from diagnosis and throughout the long-term follow-up of CML (follow up continues after treatment stopped). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT01066468 -
Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders.
|
Phase 1 | |
| Completed |
NCT00428909 -
Effect of Imatinib Mesylate and the Pharmacokinetics of Acetaminophen/Paracetamol in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
|
Phase 1 | |
| Completed |
NCT04126707 -
The Absorption, Metabolism and Excretion of [14C] HQP1351 in Humans
|
Phase 1 | |
| Active, not recruiting |
NCT02061800 -
CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant
|
Phase 1/Phase 2 | |
| Completed |
NCT00488592 -
Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers
|
Phase 2 | |
| Terminated |
NCT03615105 -
Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors
|
Phase 2 | |
| Recruiting |
NCT02790515 -
Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation
|
Phase 2 | |
| Active, not recruiting |
NCT03849651 -
TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies
|
Phase 2 | |
| Withdrawn |
NCT01605981 -
Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase.
|
Phase 4 | |
| Completed |
NCT02363868 -
Healthcare Costs Among Patients With CML Receiving Dasatinib or Nilotinib in a Commercial and Medicare Population
|
N/A | |
| Completed |
NCT00433745 -
Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy
|
Phase 2 | |
| Not yet recruiting |
NCT04709731 -
Cardiovascular Assessment of Ponatinib as Third Line Treatment in Chronic Phase Chronic Myeloid Leukemia
|
Phase 2 | |
| Recruiting |
NCT03481868 -
EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors
|
N/A | |
| Recruiting |
NCT02889003 -
Second STOP After Pioglitazone Priming in CML Patients
|
Phase 2 | |
| Completed |
NCT02733445 -
Metabolic Outcomes in Patients Receiving Tyrosine Kinase Inhibitor (TKI) Therapy With Dasatinib or Nilotinib
|
N/A | |
| Active, not recruiting |
NCT03746054 -
Evaluation of a Cardiovascular Active Prevention in Chronic Myeloid Leukemia on the Cardiovascular Morbi-mortality
|
Phase 3 | |
| Completed |
NCT01667133 -
A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)
|
Phase 1/Phase 2 | |
| Completed |
NCT00720785 -
Natural Killer Cells and Bortezomib to Treat Cancer
|
Phase 1 | |
| Approved for marketing |
NCT01592136 -
Expanded Access Program of Ponatinib
|
N/A |